Amprologix
- Company typePrivate
- Founded2018
- HeadquartersPlymouth, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Amprologix firmographics
Firmographics- Name
- Amprologix
- Legal name
- Amprologix Limited
- Website
- https://amprologix.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Amprologix industry classification
Industry- Product category
- Novel antibiotics (antimicrobial drug discovery)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Amprologix is headquartered
LocationHeadquarters
- HQ city
- Plymouth
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Amprologix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Licensing deals with pharmaceutical companies: Amprologix plans to license its antibiotic candidates to pharmaceutical companies for commercialization. Licensing deals targeted for NI01 nasal decolonization (2026, $200M+ market) and bacterial pneumonia (2027, $5B+ market).
- Grant and public funding: Significant funding from Innovate UK Biomedical Catalyst awards (£1M for Tobraderm project) and SBRI funding (£1.2m for early R&D). These grants support pre-clinical development and late-preclinical testing.
- Series A and subsequent funding rounds: Company has raised £740,000 in pre-Series A funding (October 2025) with plans for additional funds for first human trials in 2026. Target £5M Series-A funding for 2025 skin infection clinical trials.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Amprologix product offering
Product offeringCore offering
Amprologix develops Epidermicin NI01, a potent bactericidal peptide antibiotic and lead compound with no known resistance liabilities, targeting MRSA nasal decolonization, bacterial pneumonia, and topical skin/wound infections. The company also operates a proprietary AI-driven antimicrobial discovery platform that uses machine learning to identify and optimize novel peptide antibiotic candidates derived from the epidermicin family and deep-sea microorganisms. Its development pipeline is supported by an exclusively licensed compound family originally discovered by Prof Mat Upton at Manchester University.
Product overview
Amprologix is pioneering a family of new antibiotics to combat antimicrobial resistance. The core offering centers on Epidermicin NI01, a potent bactericidal peptide antibiotic with no known resistance liabilities. The company's portfolio includes the NI01 Family of novel therapeutics and an AI-Driven Antimicrobial Discovery Platform that accelerates drug candidate identification. The Tobraderm Project advances NI01 through late-preclinical testing for skin and wound infections. Together, these products form a pipeline targeting nasal decolonization (MRSA), bacterial pneumonia, and topical skin infections.
Differentiator
Problem solved
Functional benefit
Products and services
- Epidermicin NI01 Amprologix's lead antibiotic compound, a potent bactericidal peptide antibiotic with no known resistance liabilities. It is being developed for nasal decolonization of MRSA (targeted for a 2026 licensing deal in a US$200M+ market), treatment of bacterial pneumonia (targeted for a 2027 licensing deal in a US$5B+ market), and topical use against skin and wound infections including impetigo and chronic wounds.
- NI01 Family (Epidermicin peptide family) A family of novel peptide therapeutics derived from minor modifications to the NI01 peptide sequence, offering a wide range of potent yet narrow-spectrum antibacterial activity against multiple bacterial pathogens. The family targets indications including MRSA, bacterial pneumonia, and surface skin infections, and represents an entirely new class of antibiotic drugs with no known resistance liabilities.
Quantifiable outcome
- NI01 at 3% concentration matched efficacy of Bactroban (mupirocin) in reducing MRSA bacteria in wound infection model with no observed resistance development
- +2 more outcomes
Companies that use Amprologix
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Amprologix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
Amprologix partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, minor and moderate.
- University of PlymouthcoreAmprologix was launched in 2018 in collaboration with University of Plymouth. CSO Prof Mat Upton is a professor at the university. The partnership focuses on translational research and antimicrobial discovery.
- Ingenza LTDcoreWorld-leading biotechnology company partnered with Amprologix for manufacturing of antibiotic compounds.
- STFC (Science & Technology Facilities Council)corePartnership to utilize cutting-edge machine learning algorithms to improve antibiotic properties through Amprologix's AI-driven drug discovery.
- RefLab ApS (Copenhagen, Denmark)minorCollaboration using ex vivo human skin microdialysis model to test pseudo-allergic reactions for NI01 topical skin therapy, without using animal models.
- InClincoreGlobal CRO supporting both pre-clinical and clinical development of epidermicin NI01.
- National Physical Laboratory (UK)minorCollaboration with Dr Max Ryadnov to publish data on the novel mode of action of epidermicin NI01, published in iScience.
- Saudi Biotechnology AcceleratormoderateAmprologix participated in the 2025 Accelerator Programme, attending the Final Forum in Riyadh. Part of Saudi Arabia's Vision 2030 strategy to become a regional biotechnology hub.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Amprologix competitors and assessment
Company assessmentDirect peers
- Paratek Pharmaceuticals: US-based commercial-stage biopharma that developed and markets Nuzyra (omadacycline), a novel antibiotic approved for community-acquired pneumonia and skin infections. Directly comparable to Amprologix as a developer of branded, novel-mechanism antibiotics targeting similar indications and the AMR problem.
- Melinta Therapeutics: US specialty biopharma with a portfolio of branded antibiotics (e.g., Baxdela) for serious and drug-resistant infections. Comparable as a focused commercial-stage novel antibiotics developer serving the same prescriber base (hospitals treating resistant infections) that Amprologix ultimately targets via licensing.
- Iterum Therapeutics: Clinical-stage biopharma developing oral and IV antibiotics (e.g., sulopenem) for multi-drug resistant infections including community-acquired pneumonia and complicated UTIs. Comparable as a late-clinical developer of branded antibiotics targeting priority pathogens on the WHO list that Amprologix addresses.
- BioVersys: Switzerland-based clinical-stage AMR biotech developing small-molecule antibiotics (e.g., alpibectir/BVL-GSK098) to overcome resistance in priority pathogens. Comparable as a European AMR-focused biotech pursuing a licensing-oriented business model against similar bacterial targets.
- Helperby Therapeutics: UK-based clinical-stage company developing antibiotic resistance breakers and novel combinations to revive existing antibiotics. Comparable as a UK-headquartered AMR biotech in the same geographic ecosystem with a similar licensing/partnership-oriented commercial strategy.
Emerging players
- Adaptive Phage Therapeutics: US clinical-stage biotech developing phage-based therapies against drug-resistant bacterial infections including MRSA. Comparable as a developer of novel non-traditional antimicrobials (peptides vs. phages) pursuing the same hospital/ID-physician customer base for resistant infections.
- Locus Biosciences: US clinical-stage biotech developing engineered phage and CRISPR-enhanced antimicrobials targeting priority pathogens. Comparable as a technology-driven antimicrobial developer (AI/synthetic biology vs. CRISPR engineering) advancing novel modalities for AMR.
- Vedanta Biosciences: Clinical-stage biotech developing defined bacterial consortia to address recurrent C. difficile and other infection-driven indications. Comparable as a developer of novel microbiome-derived or microbiome-adjacent therapeutics for infectious disease, sharing a science-first licensing-friendly posture.
Broad incumbents
- GSK (GlaxoSmithKline): Global pharma with a dedicated antibacterial R&D effort and historical leadership in novel antibiotic commercialization. Comparable as a likely licensing partner for Amprologix and a broader incumbent that shapes market access, pricing benchmarks, and licensing deal economics in the AMR space.
- Pfizer: Global pharma with an active AMR portfolio (e.g., recent acquisition of Arixa Pharmaceuticals) and decades of antibiotic commercialization experience. Comparable as a likely large-pharma licensing counterparty and as a benchmark for the broader AMR competitive landscape Amprologix must navigate.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Amprologix social profiles
Digital presenceAmprologix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Amprologix leadership team
Management profileNumber of profiles
Profiles4 records
Amprologix funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Amprologix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Amprologix
What does Amprologix do?
Amprologix develops Epidermicin NI01, a potent bactericidal peptide antibiotic and lead compound with no known resistance liabilities, targeting MRSA nasal decolonization, bacterial pneumonia, and topical skin/wound infections. The company also operates a proprietary AI-driven antimicrobial discovery platform that uses machine learning to identify and optimize novel peptide antibiotic candidates derived from the epidermicin family and deep-sea microorganisms. Its development pipeline is supported by an exclusively licensed compound family originally discovered by Prof Mat Upton at Manchester University.
Is Amprologix a public or private company?
Amprologix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Amprologix founded?
Amprologix was founded in 2018. It employs 1 to 10 people.
Where is Amprologix based?
Amprologix is headquartered in Plymouth, United Kingdom, in the Europe region.
How does Amprologix make money?
Three revenue lines are on record. Licensing deals with pharmaceutical companies are the primary driver. The others are grant and public funding and series A and subsequent funding rounds.
Who are Amprologix's main competitors?
Direct peers on record are Paratek Pharmaceuticals, Melinta Therapeutics, Iterum Therapeutics, BioVersys and Helperby Therapeutics. Emerging players are Adaptive Phage Therapeutics, Locus Biosciences and Vedanta Biosciences. Broad incumbents are GSK (GlaxoSmithKline) and Pfizer.
Does Amprologix have an API?
No public API is recorded for Amprologix.
What industry is Amprologix in?
Amprologix's product category is Novel antibiotics (antimicrobial drug discovery). Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2834.